Form 4: Harmony Biosciences CFO Sells Shares via 10b5-1 Plan
Insider Transaction Report
Harmony Biosciences Chief Financial Officer Sandip Kapadia sold 20,961 shares of common stock for a weighted average price of $35.9159 per share through a pre-arranged Rule 10b5-1 trading plan.
Summary
- Sandip Kapadia, Chief Financial Officer of Harmony Biosciences Holdings, Inc. (HRMY), reported a sale of common stock.
- The transaction involved the disposition of 20,961 shares of common stock.
- The shares were sold on January 15, 2026, at a weighted average price of $35.9159 per share.
- The sales were executed pursuant to a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction.
- The selling price ranged from $35.68 to $36.10 across multiple transactions.
- Following this transaction, Mr. Kapadia beneficially owns 0 shares of common stock directly.
Sentiment
Score: 5
Explanation: The filing reports a routine, pre-scheduled insider stock sale under a 10b5-1 plan, which is generally considered neutral. It does not provide new information about the company's operational or financial performance.
Positives
- The sale was conducted under a Rule 10b5-1 trading plan, which helps mitigate concerns about insider trading by pre-scheduling transactions and demonstrating adherence to corporate governance best practices.
Negatives
- An insider sale, even if pre-planned, can sometimes be perceived negatively by investors, potentially signaling a lack of confidence, although this is often a routine liquidity event for executives.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This filing reports a routine insider transaction for Harmony Biosciences and does not provide information relevant to broader industry trends or competitor analysis.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | The reported sale of common stock by the Chief Financial Officer was effected pursuant to a Rule 10b5-1 trading plan, which is a pre-arranged plan designed to comply with insider trading laws. | 01/15/2026 | The use of a 10b5-1 plan demonstrates adherence to corporate governance best practices regarding insider stock transactions, reducing the perception of opportunistic selling. |
Stakeholder Impact
- Shareholders: May view the insider sale with slight caution, though the 10b5-1 plan mitigates concerns. The direct beneficial ownership of 0 shares after the transaction might raise questions about long-term alignment, but this is a single, pre-scheduled transaction.
Key Dates
| Date | Description |
|---|---|
| 01/15/2026 | Date of transaction (sale of common stock) |
| 01/20/2026 | Date Form 4 was signed and filed |
Keywords
Harmony Biosciences, HRMY, Sandip Kapadia, CFO, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Equity Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.